Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56023 | 1.00 | MTOR (0.71) | MTORPIK3CAPIK3CDHDAC3HDAC1 | |
| SCHEMBL56247 | 0.92 | MTOR (0.62) | MTORPIK3CAPIK3CDHDAC3HDAC1 | |
| SCHEMBL56492 | 0.87 | MTOR (0.69) | MTORPIK3CAPIK3CD | |
| SCHEMBL55518 | 0.87 | MTOR (0.69) | MTORPIK3CAPIK3CD | |
| SCHEMBL55663 | 0.86 | MTOR (0.68) | MTORPIK3CAPIK3CD | |
| SCHEMBL55783 | 0.86 | MTOR (0.68) | MTORPIK3CAPIK3CD | |
| SCHEMBL57780 | 0.84 | PIK3CA (1.00) | MTORPIK3CAPIK3CD | |
| SCHEMBL56289 | 0.84 | PIK3CA (1.00) | MTORPIK3CAPIK3CD | |
| SCHEMBL55678 | 0.82 | PIK3CA (1.00) | MTORPIK3CAPIK3CD | |
| SCHEMBL54276 | 0.82 | PIK3CA (0.83) | MTORPIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129371-B2 | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors | WYETH LLC (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098086-A1 | THIENOPYRIMIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | MTOR 1/4885PIK3CA 2/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.